| Literature DB >> 31392101 |
Shucai Xie1, Xili Jiang2, Jianquan Zhang1, Shaowei Xie1, Yongyong Hua1, Rui Wang1, Yijun Yang1.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is a common malignant tumor affecting the digestive system and causes serious financial burden worldwide. Hepatitis B virus (HBV) is the main causative agent of HCC in China. The present study aimed to investigate the potential mechanisms underlying HBV-related HCC and to identify core biomarkers by integrated bioinformatics analyses.Entities:
Keywords: Bioinformatic analysis; Differentially expressed genes; Hepatocellular carcinoma; RobustRankAggreg
Year: 2019 PMID: 31392101 PMCID: PMC6677124 DOI: 10.7717/peerj.7408
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Details of the GEO HBV-related HCC data.
| GEO | Sample | Platform | Normal | Tumor | Reference |
|---|---|---|---|---|---|
|
| hepatocellular carcinoma (HBV) |
| 5 | 5 | |
|
| hepatocellular carcinoma (HBV) |
| 91 | 49 | |
|
| hepatocellular carcinoma (HBV) |
| 21 | 21 | |
|
| hepatocellular carcinoma (HBV) |
| 37 | 70 |
Notes.
gene expression omnibus
Information of DEGs screened from each dataset.
| GEO | Sample | Number of DEGs | Number of upregulated genes | Number of downregulated genes |
|---|---|---|---|---|
|
| hepatocellular carcinoma (HBV) | 648 | 257 | 391 |
|
| hepatocellular carcinoma (HBV) | 1,034 | 409 | 634 |
|
| hepatocellular carcinoma (HBV) | 1,171 | 360 | 811 |
|
| hepatocellular carcinoma (HBV) | 580 | 167 | 413 |
Notes.
gene expression omnibus
Figure 1Differential expression genes between the two groups of samples in each dataset.
(A) GSE19665, (B) GSE55092, (C) GSE94660, (D) GSE121248. The red dots represent the upregulated genes based on an adjusted P < 0.05 and log fold change > 1; the green dots represent the downregulated genes based on an adjusted P < 0.05 and log fold change < 1; the black spots represent genes with no significant difference in expression.
Figure 2Log FC Heatmap of the top 20 DEGs (upregulated genes and downregulated genes) expression in all datasets.
The abscissa represent the GEO IDs, the ordinate represents the gene name, the red represents log FC > 0, the white represents log FC = 0, the green represents log FC < 0 and the value in the box represents the log FC value.
Figure 3(A) GO analysis of upregulated DEGs. (B) GO analysis of downregulated DEGs. (C) KEGG pathway of DEGs.
Top 15 GO enrichment terms of differentially expressed genes associated with hepatitis B-related hepatocellular carcinoma.
| BP | GO:0007049∼cell cycle | 43 | 38.39286 | 7.63E-28 | |
| BP | GO:0000279∼M phase | 32 | 28.57143 | 2.48E-27 | |
| BP | GO:0022403∼cell cycle phase | 33 | 29.46429 | 1.59E-25 | |
| BP | GO:0007067∼mitosis | 27 | 24.10714 | 2.03E-25 | |
| BP | GO:0000280∼nuclear division | 27 | 24.10714 | 2.03E-25 | |
| CC | GO:0005819∼ mitotic spindle | 21 | 18.75 | 1.43E-21 | |
| CC | GO:0015630∼microtubule cytoskeleton | 24 | 21.42857 | 2.84E-13 | |
| CC | GO:0044430∼cytoskeletal part | 25 | 22.32143 | 3.19E-09 | |
| CC | GO:0005856∼cytoskeleton | 28 | 25 | 5.91E-08 | |
| CC | GO:0000922∼spindle pole | 7 | 6.25 | 6.75E-08 | |
| MF | GO:0005524∼ATP binding | 24 | 21.42857 | 3.45E-05 | |
| MF | GO:0032559∼adenyl ribonucleotide binding | 24 | 21.42857 | 4.27E-05 | |
| MF | GO:0030554∼adenyl nucleotide binding | 24 | 21.42857 | 9.64E-05 | |
| MF | GO:0001883∼purine nucleoside binding | 24 | 21.42857 | 1.22E-04 | |
| MF | GO:0001882∼nucleoside binding | 24 | 21.42857 | 1.35E-04 | |
| BP | GO:0055114∼oxidation reduction | 36 | 16.66667 | 7.03E-14 | |
| BP | GO:0045087∼innate immune response | 15 | 6.944444 | 1.67E-09 | |
| BP | GO:0006956∼complement activation | 10 | 4.62963 | 1.78E-09 | |
| BP | GO:0009611∼response to wounding | 27 | 12.5 | 1.84E-09 | |
| BP | GO:0002541∼activation of plasma proteins involved in acute inflammatory response | 10 | 4.62963 | 2.23E-09 | |
| CC | GO:0005576∼extracellular region | 83 | 38.42593 | 2.05E-21 | |
| CC | GO:0044421∼extracellular region part | 50 | 23.14815 | 9.40E-16 | |
| CC | GO:0005615∼extracellular space | 41 | 18.98148 | 8.87E-15 | |
| CC | GO:0005792∼microsome | 17 | 7.87037 | 2.50E-07 | |
| CC | GO:0042598∼vesicular fraction | 17 | 7.87037 | 3.70E-07 | |
| MF | GO:0009055∼electron carrier activity | 23 | 10.64815 | 1.17E-13 | |
| MF | GO:0019825∼oxygen binding | 12 | 5.555556 | 5.61E-12 | |
| MF | GO:0005506∼iron ion binding | 22 | 10.18519 | 5.88E-10 | |
| MF | GO:0020037∼heme binding | 14 | 6.481481 | 6.05E-09 | |
| MF | GO:0046906∼tetrapyrrole binding | 14 | 6.481481 | 1.33E-08 |
Notes.
biological process
cellular component
molecular function
gene ontology
KEGG pathway analysis of differentially expressed genes associated with hepatitis B-related hepatocellular carcinoma.
| hsa00830:Retinol metabolism | 13 | 3.963415 | 3.73E-09 | CYP3A4, CYP2B6, CYP2C9, CYP2C18, CYP2C8, CYP26A1, ADH1A, CYP1A2, CYP4A11, ADH4, CYP2A6, CYP2A7, RDH16 |
| hsa00982:Drug metabolism | 12 | 3.658537 | 2.06E-07 | CYP3A4, CYP2C18, CYP2C9, CYP2B6, ADH4, CYP2C8, GSTZ1, CYP2A6, ADH1A, CYP2A7, CYP1A2, ALDH3A1 |
| hsa00980:Metabolism of xenobiotics by cytochrome P450 | 11 | 3.353659 | 1.39E-06 | AKR1C3, CYP3A4, CYP2C18, CYP2C9, CYP2B6, ADH4, CYP2C8, GSTZ1, ADH1A, CYP1A2, ALDH3A1 |
| hsa00232:Caffeine metabolism | 5 | 1.52439 | 1.11E-05 | XDH, NAT2, CYP2A6, CYP2A7, CYP1A2 |
| hsa00380:Tryptophan metabolism | 7 | 2.134146 | 3.62E-04 | AADAT, TDO2, ACMSD, IDO2, KMO, CYP1A2, INMT |
| hsa00591:Linoleic acid metabolism | 6 | 1.829268 | 4.98E-04 | CYP3A4, CYP2C18, CYP2C9, AKR1B10, CYP2C8, CYP1A2 |
| hsa00983:Drug metabolism | 7 | 2.134146 | 5.42E-04 | CYP3A4, XDH, NAT2, CDA, CYP2A6, CYP2A7, TK1 |
| hsa04610:Complement and coagulation cascades | 8 | 2.439024 | 0.001332 | C8A, C8B, C7, C9, C6, KLKB1, F9, PLG |
| hsa00590:Arachidonic acid metabolism | 7 | 2.134146 | 0.002231 | AKR1C3, CYP4A11, CYP2C18, CYP2C9, CYP2B6, CYP2C8, CYP4F2 |
| hsa04110:Cell cycle | 10 | 3.04878 | 0.003227 | CCNE2, CCNB1, CDC6, MAD2L1, BUB1B, TTK, CDC20, MCM2, PTTG1, CCNA2 |
| hsa00350:Tyrosine metabolism | 6 | 1.829268 | 0.004034 | ADH4, GSTZ1, ADH1A, TAT, ALDH3A1, HPD |
| hsa04115:p53 signaling pathway | 7 | 2.134146 | 0.005932 | STEAP3, CCNE2, CCNB1, RRM2, IGF1, THBS1, IGFBP3 |
| hsa05020:Prion diseases | 5 | 1.52439 | 0.009832 | C8A, C8B, C7, C9, C6 |
| hsa00140:Steroid hormone biosynthesis | 5 | 1.52439 | 0.024978 | AKR1C3, CYP3A4, HSD17B2, SRD5A2, AKR1D1 |
| hsa00260:Glycine, serine and threonine metabolism | 4 | 1.219512 | 0.038725 | SDS, AGXT2, GNMT, GLDC |
| hsa04114:Oocyte meiosis | 7 | 2.134146 | 0.05109 | CCNE2, CCNB1, MAD2L1, IGF1, CDC20, AURKA, PTTG1 |
| hsa00010:Glycolysis/Gluconeogenesis | 5 | 1.52439 | 0.057701 | ADH4, ALDOB, FBP1, ADH1A, ALDH3A1 |
| hsa00071:Fatty acid metabolism | 4 | 1.219512 | 0.072811 | CYP4A11, ADH4, ADH1A, ACSL4 |
| hsa05322:Systemic lupus erythematosus | 6 | 1.829268 | 0.093168 | C8A, C8B, C7, C9, C6, HIST1H4H |
| hsa00360:Phenylalanine metabolism | 3 | 0.914634 | 0.099295 | TAT, ALDH3A1, HPD |
The top 10 most degree values hub genes between HBV-related HCC and normal samples.
Up indicated that the gene was identifed as up-regulated in HCC; Down indicated that the gene was reported as down-regulated. UN suggested the gene has not been reported in current HCC associated studies.
| Gene symbol | Gene description | logFC | Degree | Up/down |
|---|---|---|---|---|
| SHCBP1 | SHC binding and spindle associated 1 | 1.211943105 | 43 | Up |
| FOXM1 | forkhead box M1 | 1.832558689 | 43 | Up |
| KIF4A | kinesin family member 4A | 1.850277648 | 43 | Up |
| ANLN | anillin actin binding protein | 1.982343654 | 43 | Up |
| KIF15 | kinesin family member 15 | 1.247277869 | 43 | UN |
| KIF18A | kinesin family member 18A | 1.26437819 | 43 | Up |
| FANCI | FA complementation group I | 1.269987824 | 43 | UN |
| NEK2 | NIMA related kinase 2 | 1.652396787 | 43 | Down |
| ECT2 | epithelial cell transforming 2 | 1.418475417 | 43 | Up |
| RAD51AP1 | RAD51 associated protein 1 | 1.585151756 | 42 | UN |
Notes.
fold change
Figure 4PPI network of module 1 (A), module 2 (B) and hierarchical clustering of hub genes was constructed using UCSC (C).
(A and B) Circles represent genes, lines represent interactions between gene-encoded proteins and line colors represent evidence of interactions between proteins. (C) The samples under the pink bar are normal samples and the samples under the blue bar are HCC samples. Upregulation of genes is marked in red; downregulation of genes is marked in blue.
KEGG enrichment of genes in the top 2 modules.
| Module | Term | Count | % | Genes | |
|---|---|---|---|---|---|
| Modul1 | hsa04110:Cell cycle | 10 | 18.18182 | 5.06E-11 | CCNE2, CCNB1, CDC6, MAD2L1, BUB1B, TTK, CDC20, MCM2, PTTG1, CCNA2 |
| hsa04114:Oocyte meiosis | 6 | 10.90909 | 2.18E-05 | CCNE2, CCNB1, MAD2L1, CDC20, AURKA, PTTG1 | |
| hsa04115:p53 signaling pathway | 3 | 5.454545 | 0.021056 | CCNE2, CCNB1, RRM2 | |
| hsa04914:Progesterone-mediated oocyte maturation | 3 | 5.454545 | 0.032616 | CCNB1, MAD2L1, CCNA2 | |
| Modul2 | hsa04610:Complement and coagulation cascades | 5 | 45.45455 | 3.11E-08 | C8A, C8B, C6, KLKB1, F9 |
| hsa05020:Prion diseases | 3 | 27.27273 | 2.74E-04 | C8A, C8B, C6 | |
| hsa05322:Systemic lupus erythematosus | 3 | 27.27273 | 0.002195 | C8A, C8B, C6 |
Figure 5The biological process analysis of the hub genes.
(A) The biological process analysis of hub genes was constructed using BiNGO. The color depth of nodes refers to the corrected P-value of ontologies. The size of nodes refers to the numbers of genes that are involved in the ontologies. P < 0.05 was considered statistically significant. (B) Hub genes and their co-expression genes were analyzed using cBioPortal. Nodes with bold black outline represent hub genes. Nodes with thin black outline represent the co-expression genes.
Figure 6(A, B) Disease-free survival analyses and (C–G) overall survival of hub genes were performed using cBioPortal online platform.
P < 0.05 was considered statistically significant.
Figure 7Heat maps of ANLN (A) and KIF18A (B) gene expression in multiple clinical hepatocellular carcinoma samples vs. normal tissues using Oncomine analysis.